Full file name source

core/agent.py

@@ -166,13 +166,13 @@ Your primary purpose is to provide evidence-based clinical guidance on lung canc
   
   **PART 1: INLINE CITATIONS** - Add a citation immediately after EACH section or statement in your answer:
   * After each clinical statement, recommendation, or data point, add an inline citation in parentheses
-  * Format: (Source: [source name without file extension], Page: [page number], Provider: [provider])
-  * Example: "Local authorities must use coordinated campaigns to raise awareness (Source: NICE, Page: 6, Provider: NICE)."
+  * Format: (Source: [Provider + full document title without file extension], Page: [page number], Provider: [provider])
+  * Example: "Local authorities must use coordinated campaigns to raise awareness (Source: NICE Systemic anti-cancer therapy for advanced  non‑small‑cell lung cancer, Page: 6, Provider: NICE)."
   * If a section uses multiple pages, cite each: "Structure measures include... (Page: 6). Process measures include... (Page: 15). Outcome measures include... (Page: 8)."
   
   **PART 2: COMPREHENSIVE CITATION LIST AT END** - After your complete answer, add a section titled "**References**" that lists ALL pages cited:
-  * Format: (Source: [source name without file extension], Pages: [all page numbers in order], Provider: [provider name], Location: [specific sections/tables used])
-  * Example: (Source: NICE, Pages: 6, 8, 15, Provider: NICE, Location: Quality Statement 1 - Structure, Process, and Outcome measures)
+  * Format: (Source: [Provider + full document title without file extension], Pages: [all page numbers in order], Provider: [provider name], Location: [specific sections/tables used])
+  * Example: (Source: NICE Systemic anti-cancer therapy for advanced  non‑small‑cell lung cancer, Pages: 6, 8, 15, Provider: NICE, Location: Quality Statement 1 - Structure, Process, and Outcome measures)
   
 - **PAGE CITATION RULE - EXTREMELY IMPORTANT**: 
   * BEFORE writing your answer, review ALL retrieved pages (including context pages) and identify EVERY page that contains information you will use

core/tools.py

@@ -184,6 +184,10 @@ def _build_citation(index: int, metadata: dict, content: str, include_provider:
         source = os.path.splitext(source)[0]
     page = metadata.get("page_number", "?")
     provider = metadata.get("provider", "unknown")
+    # Ensure source displays as "<PROVIDER> <file-stem>" unless it already starts with the provider
+    if isinstance(source, str) and isinstance(provider, str) and provider and source:
+        if not source.lower().startswith(provider.lower()):
+            source = f"{provider} {source}"
     disease = metadata.get("disease", "unknown")
     is_context = metadata.get("context_enrichment", False)
     

data/medical_terms_cache.json

@@ -4,60 +4,60 @@
       "esmo"
     ],
     "esmo": [
+      "european society for medical oncology",
       "the european society for medical\noncology",
+      "european\nsociety of medical oncology",
       "european society of medical oncology",
-      "european society for medical oncology",
       "european society for\nmedical oncology",
-      "the european society for medical oncology",
-      "european\nsociety of medical oncology"
+      "the european society for medical oncology"
     ],
     "american society of clinical\n\noncology": [
       "asco"
     ],
     "asco": [
       "american society of clinical\n\noncology",
-      "american society of clinical oncology",
-      "american\nsociety of clinical oncology",
       "s note\n\nthis american society of clinical oncology",
-      "md american society of clinical oncology",
       "journal of clinical oncology",
-      "inc"
+      "inc",
+      "american\nsociety of clinical oncology",
+      "md american society of clinical oncology",
+      "american society of clinical oncology"
     ],
     "italian association of medical oncology": [
       "aiom"
     ],
     "aiom": [
-      "italian association\nof medical oncology",
-      "italian association of medical oncology"
+      "italian association of medical oncology",
+      "italian association\nof medical oncology"
     ],
     "national comprehensive cancer network": [
       "nccn"
     ],
     "nccn": [
       "national comprehensive cancer network",
-      "leading american cancer centers",
-      "vs insurance-based"
+      "vs insurance-based",
+      "leading american cancer centers"
     ],
     "non-small cell lung cancer": [
       "nsclc"
     ],
     "nsclc": [
-      "e-mutant advanced non-small cell lung cancer",
-      "advanced non-small cell lung cancer",
-      "robotic lobectomy for non-small cell lung cancer",
       "non-small-cell lung cancer",
+      "iii non-small-cell lung cancer",
       "small cell lung cancer",
-      "mutant advanced non-small cell lung cancer",
-      "advanced non-small-cell lung cancer",
       "small-cell\nlung cancer",
-      "small-cell lung cancer",
-      "iii non-small-cell lung cancer",
-      "stage iii non small cell lung cancer",
+      "advanced non-small cell lung cancer",
       "lung cancer",
       "non-small cell lung cancer",
+      "small-cell lung cancer",
       "cancer",
+      "e-mutant advanced non-small cell lung cancer",
       "small cell\nlung cancer",
-      "-rearranged advanced non-small-cell lung cancer"
+      "advanced non-small-cell lung cancer",
+      "-rearranged advanced non-small-cell lung cancer",
+      "robotic lobectomy for non-small cell lung cancer",
+      "mutant advanced non-small cell lung cancer",
+      "stage iii non small cell lung cancer"
     ],
     "american\nsociety of clinical oncology": [
       "asco"
@@ -76,19 +76,19 @@
     ],
     "glides": [
       "guidelines into decision support",
-      "using the guidelines into decision support",
-      "using the guidelines into decision\nsupport"
+      "using the guidelines into decision\nsupport",
+      "using the guidelines into decision support"
     ],
     "for all the newly\neuropean medicines agency": [
       "ema"
     ],
     "ema": [
-      "european medicines agency",
-      "and the european medicines agency",
-      "and the european medicines\nagency",
       "for all the newly\neuropean medicines agency",
+      "and the european medicines\nagency",
+      "european medicines agency",
       "not european medicines agency",
-      "for all the newly european medicines agency"
+      "for all the newly european medicines agency",
+      "and the european medicines agency"
     ],
     "evaluates treatments with curative intent": [
       "such\nas adjuvant chemotherapy",
@@ -131,10 +131,10 @@
       "bsc"
     ],
     "bsc": [
-      "or best supportive\ncare",
-      "leads to\nincreased dfs versus best supportive care",
       "or best supportive care",
-      "leads to increased dfs versus best supportive care"
+      "or best supportive\ncare",
+      "leads to increased dfs versus best supportive care",
+      "leads to\nincreased dfs versus best supportive care"
     ],
     "author affiliations\nand support\n\ninformation": [
       "if\n\napplicable"
@@ -152,17 +152,17 @@
       "rcts"
     ],
     "rcts": [
+      "controlled trials",
       "clinical trials",
-      "two randomized control trials",
-      "controlled trials"
+      "two randomized control trials"
     ],
     "the primary end point was disease-free\nsurvival": [
       "dfs"
     ],
     "dfs": [
-      "the primary end point was disease-free survival",
       "disease-free survival",
-      "the primary end point was disease-free\nsurvival"
+      "the primary end point was disease-free\nsurvival",
+      "the primary end point was disease-free survival"
     ],
     "joint cancer care ontario": [
       "cco"
@@ -177,75 +177,75 @@
       "inst"
     ],
     "inst": [
+      "advaxis",
+      "bristol myers squibb",
+      "blueprint medicines",
+      "dizal pharma",
       "crispr\ntherapeutics",
-      "merck",
-      "trizell",
-      "anheart therapeutics",
-      "inc",
-      "regeneron",
-      "bms",
-      "bristol-myers squibb",
-      "lilly",
-      "oric pharmaceuticals",
-      "elevation oncology",
-      "amgen",
-      "janssen oncology",
-      "verastem",
-      "medimmune",
+      "astex pharmaceuticals",
+      "revolution medicines",
       "black diamond therapeutics",
-      "janssen",
+      "verastem",
       "msd",
+      "sutro biopharma",
+      "novartis",
+      "bristol myers\nsquibb",
+      "merck",
+      "oncomed",
+      "gsk",
+      "black diamond\ntherapeutics",
+      "therapeutics",
       "guardant health",
-      "palobiofarma",
-      "constellation pharmaceuticals",
-      "neogenomics",
-      "blueprint medicines",
-      "nuvation bio",
+      "crispr therapeutics",
+      "jazz pharmaceuticals",
+      "amgen",
+      "calithera biosciences",
+      "oric pharmaceuticals",
+      "inc",
+      "dohme",
+      "bristol-myers squibb",
+      "astra zeneca",
+      "harpoon therapeutics",
       "pfizer",
-      "therapeutics",
-      "gsk",
+      "bms",
+      "nuvation bio",
+      "turning point therapeutics",
       "pharmamar",
-      "mirati therapeutics",
-      "glaxosmithkline",
-      "revolution medicines",
-      "dohme",
-      "crispr therapeutics",
+      "trizell",
+      "roche",
+      "arcus biosciences",
       "summit therapeutics",
-      "harpoon therapeutics",
-      "macrogenics",
-      "jazz pharmaceuticals",
-      "glaxosmithkline canada",
-      "genentech",
+      "astrazeneca",
+      "astrazeneca canada",
+      "lilly",
+      "forward",
+      "neogenomics",
       "takeda",
-      "astra zeneca",
-      "cullinan oncology",
+      "medimmune",
       "abbvie",
-      "bristol myers\nsquibb",
       "dizal\npharma",
+      "janssen oncology",
+      "glaxosmithkline canada",
+      "polaris",
+      "mirati therapeutics",
       "puma biotechnology",
-      "advaxis",
-      "novartis",
+      "cullinan oncology",
+      "glaxosmithkline",
+      "constellation pharmaceuticals",
       "vivace therapeutics",
-      "turning point therapeutics",
-      "astex pharmaceuticals",
-      "merck serono",
-      "oncomed",
-      "astrazeneca",
-      "exelixis",
+      "palobiofarma",
+      "bristol myers squibb foundation",
       "bayer",
-      "dizal pharma",
-      "inhibrx",
-      "calithera biosciences",
-      "polaris",
-      "arcus biosciences",
-      "astrazeneca canada",
-      "black diamond\ntherapeutics",
       "boehringer ingelheim",
-      "sutro biopharma",
-      "bristol myers squibb",
-      "forward",
-      "roche",
-      "bristol myers squibb foundation"
+      "regeneron",
+      "inhibrx",
+      "exelixis",
+      "merck serono",
+      "janssen",
+      "macrogenics",
+      "elevation oncology",
+      "genentech",
+      "anheart therapeutics"
     ],
     "pfizer": [
       "inst"
@@ -254,8 +254,8 @@
       "inst"
     ],
     "bristol-myers squibb": [
-      "bms",
-      "inst"
+      "inst",
+      "bms"
     ],
     "medimmune": [
       "inst"
@@ -304,18 +304,18 @@
       "continued"
     ],
     "continued": [
-      "medical guideline document - esmo open references",
+      "all recommendations",
       "the bottom line",
-      "all recommendations"
+      "medical guideline document - esmo open references"
     ],
     "salvage stereotactic body radiation therapy": [
       "sbrt"
     ],
     "sbrt": [
+      "stereotactic body radiotherapy",
       "salvage stereotactic body radiation therapy",
-      "fdg-pet and stereotactic body radiotherapy",
       "sabr or stereotactic body radiotherapy",
-      "stereotactic body radiotherapy"
+      "fdg-pet and stereotactic body radiotherapy"
     ],
     "oncomed": [
       "inst"
@@ -330,35 +330,35 @@
       "cap"
     ],
     "cap": [
-      "the college of american pathologists",
-      "thecollege of americanpathologists"
+      "thecollege of americanpathologists",
+      "the college of american pathologists"
     ],
     "association\nfor molecular pathology": [
       "amp"
     ],
     "amp": [
-      "association\nfor molecular pathology",
-      "association for molecular pathology"
+      "association for molecular pathology",
+      "association\nfor molecular pathology"
     ],
     "and anaplastic lymphoma kinase": [
       "alk"
     ],
     "alk": [
-      "phoma kinase",
-      "and anaplastic lymphoma kinase",
       "crizotinib-pretreated anaplastic lymphoma kinase",
-      "positive anaplastic lymphoma kinase"
+      "positive anaplastic lymphoma kinase",
+      "and anaplastic lymphoma kinase",
+      "phoma kinase"
     ],
     "immunohistochemistry": [
       "ihc"
     ],
     "ihc": [
-      "egfr fish or immunohistochemistry",
-      "immunohistochemistry"
+      "immunohistochemistry",
+      "egfr fish or immunohistochemistry"
     ],
     "merck": [
-      "german",
-      "inst"
+      "inst",
+      "german"
     ],
     "glaxosmithkline": [
       "gsk",
@@ -371,8 +371,8 @@
       "inst"
     ],
     "bristol myers\nsquibb": [
-      "bms",
-      "inst"
+      "inst",
+      "bms"
     ],
     "polaris": [
       "inst"
@@ -411,8 +411,8 @@
       "icis"
     ],
     "icis": [
-      "immune checkpoint inhibitors",
-      "neoadjuvant immune checkpoint inhibitors"
+      "neoadjuvant immune checkpoint inhibitors",
+      "immune checkpoint inhibitors"
     ],
     "american society of clinical oncology": [
       "asco"
@@ -433,13 +433,13 @@
       "inst"
     ],
     "bms": [
-      "bristol-myers squibb",
+      "bristol myers squibb",
       "inst",
+      "bristol-myers squibb",
       "bristol myers\nsquibb",
+      "bristol-myers\nsquibb",
       "celgene",
-      "bristol\nmyers squibb",
-      "bristol myers squibb",
-      "bristol-myers\nsquibb"
+      "bristol\nmyers squibb"
     ],
     "trizell": [
       "inst"
@@ -457,27 +457,27 @@
       "rct"
     ],
     "rct": [
-      "one randomized controlled trial",
+      "phase iib\nrandomised controlled trial",
       "phase iib randomised controlled trial",
-      "phase iii randomised clinical trial",
       "a phase iii randomised clinical trial",
-      "phase iib\nrandomised controlled trial"
+      "phase iii randomised clinical trial",
+      "one randomized controlled trial"
     ],
     "the primary end point of progression-free survival": [
       "pfs"
     ],
     "pfs": [
-      "the median progression-free\nsurvival",
-      "progression-free survival",
-      "and\nprogression-free survival",
-      "the median progression-free survival",
       "and progression-free survival",
-      "no\nimprovement in progression-free survival",
+      "the median progression-free survival",
       "quality of life and progression-free survival",
-      "the median\nprogression-free survival",
-      "the primary end point of progression-free survival",
+      "reported improved progression-free survival",
       "reported improved\nprogression-free survival",
-      "reported improved progression-free survival"
+      "the primary end point of progression-free survival",
+      "the median\nprogression-free survival",
+      "progression-free survival",
+      "the median progression-free\nsurvival",
+      "no\nimprovement in progression-free survival",
+      "and\nprogression-free survival"
     ],
     "adverse events": [
       "aes",
@@ -485,8 +485,8 @@
     ],
     "aes": [
       "mainly altered lipid levels",
-      "adverse events",
-      "adverse\nevents"
+      "adverse\nevents",
+      "adverse events"
     ],
     "and consolidation": [
       "for unresectable stage iii nsclc"
@@ -498,13 +498,13 @@
       "osimertinib"
     ],
     "osimertinib": [
-      "treatment is now an\negfr-targeted drug",
+      "treatment is now an egfr-targeted drug",
       "osi",
-      "treatment is now an egfr-targeted drug"
+      "treatment is now an\negfr-targeted drug"
     ],
     "inc": [
-      "asco",
-      "inst"
+      "inst",
+      "asco"
     ],
     "small cell\nlung cancer": [
       "nsclc"
@@ -519,8 +519,8 @@
       "vegf"
     ],
     "vegf": [
-      "and vascular endothelial growth factor",
-      "and vascular\nendothelial growth factor"
+      "and vascular\nendothelial growth factor",
+      "and vascular endothelial growth factor"
     ],
     "though rates of\nimmune-related aes": [
       "iraes"
@@ -530,15 +530,15 @@
       "though rates of immune-related aes"
     ],
     "bristol myers squibb": [
-      "bms",
-      "inst"
+      "inst",
+      "bms"
     ],
     "palobiofarma": [
       "inst"
     ],
     "dohme": [
-      "msd",
-      "inst"
+      "inst",
+      "msd"
     ],
     "mirati therapeutics": [
       "inst"
@@ -565,8 +565,8 @@
       "inst"
     ],
     "gsk": [
-      "glaxosmithkline",
-      "inst"
+      "inst",
+      "glaxosmithkline"
     ],
     "regeneron": [
       "inst"
@@ -624,26 +624,26 @@
       "health research methods"
     ],
     "health research methods": [
-      "asco practice guidelines staff",
-      "va asco practice guideline staff",
+      "va asco practice guidelines staff",
       "asco practice guideline staff",
-      "va asco practice guidelines staff"
+      "asco practice guidelines staff",
+      "va asco practice guideline staff"
     ],
     "in tyrosine kinase inhibitor": [
       "tki"
     ],
     "tki": [
-      "in tyrosine kinase inhibitor",
-      "tyrosine kinase inhibitor"
+      "tyrosine kinase inhibitor",
+      "in tyrosine kinase inhibitor"
     ],
     "reuss et al\n\n\n\nrate": [
       "orr"
     ],
     "orr": [
+      "rate",
       "which had an overall response rate",
-      "reuss et al\n\n\n\nrate",
       "- objective response rate",
-      "rate"
+      "reuss et al\n\n\n\nrate"
     ],
     "disease control rate": [
       "dcr"
@@ -661,11 +661,11 @@
       "dor"
     ],
     "dor": [
+      "- duration of response",
+      "the median duration of response",
       "the median\nduration of response",
       "with a median duration of response",
-      "with a median duration of\nresponse",
-      "the median duration of response",
-      "- duration of response"
+      "with a median duration of\nresponse"
     ],
     "the most common treatment-emergent adverse events": [
       "teaes"
@@ -692,8 +692,8 @@
       "inst"
     ],
     "msd": [
-      "dohme",
-      "inst"
+      "inst",
+      "dohme"
     ],
     "lilly": [
       "inst"
@@ -717,8 +717,8 @@
       "cancer care ontario"
     ],
     "cancer care ontario": [
-      "asco-ontario health",
-      "was published by asco and ontario health"
+      "was published by asco and ontario health",
+      "asco-ontario health"
     ],
     "the median progression-free\nsurvival": [
       "pfs"
@@ -734,8 +734,8 @@
     ],
     "durvalumab": [
       "if ps improves\n\nv\n\nconsolidation immunotherapy",
-      "if ps improves\n- consolidation immunotherapy",
-      "consolidation immunotherapy"
+      "consolidation immunotherapy",
+      "if ps improves\n- consolidation immunotherapy"
     ],
     "if ps improves\n\nv\n\nconsolidation immunotherapy": [
       "durvalumab"
@@ -750,16 +750,16 @@
       "bite"
     ],
     "bite": [
-      "a bispecific t-cell\nengager",
-      "a bispecific t-cell engager"
+      "a bispecific t-cell engager",
+      "a bispecific t-cell\nengager"
     ],
     "the most\ncommon ae was cytokine release syndrome": [
       "crs"
     ],
     "crs": [
+      "the most common ae was cytokine release syndrome",
       "the most\ncommon ae was cytokine release syndrome",
-      "cytokine release syndrome",
-      "the most common ae was cytokine release syndrome"
+      "cytokine release syndrome"
     ],
     "asco-ontario health": [
       "cancer care ontario"
@@ -784,13 +784,13 @@
     ],
     "fda": [
       "or food and drug administration",
-      "the food and drug administration",
-      "entrectinib received food and\ndrug administration",
       "entrectinib received food and drug administration",
-      "and the food and drug administration",
-      "and the united states food and drug administration",
+      "entrectinib received food and\ndrug administration",
       "food and drug administration",
-      "the us food and drug administration"
+      "the food and drug administration",
+      "and the united states food and drug administration",
+      "the us food and drug administration",
+      "and the food and drug administration"
     ],
     "cytokine release syndrome": [
       "crs"
@@ -813,8 +813,8 @@
     ],
     "nets": [
       "tumors",
-      "has grouped lung and thymic neuroendocrine\ntumours",
-      "has grouped lung and thymic neuroendocrine tumours"
+      "has grouped lung and thymic neuroendocrine tumours",
+      "has grouped lung and thymic neuroendocrine\ntumours"
     ],
     "small cell lung cancer": [
       "nsclc",
@@ -824,15 +824,15 @@
       "lcnec"
     ],
     "lcnec": [
-      "and\nlarge cell neuroendocrine carcinoma",
-      "and large cell neuroendocrine carcinoma"
+      "and large cell neuroendocrine carcinoma",
+      "and\nlarge cell neuroendocrine carcinoma"
     ],
     "and thymic\ncarcinoid": [
       "thc"
     ],
     "thc": [
-      "and thymic carcinoid",
-      "and thymic\ncarcinoid"
+      "and thymic\ncarcinoid",
+      "and thymic carcinoid"
     ],
     "org": [
       "esmo guidelines committee"
@@ -888,8 +888,8 @@
       "ssas"
     ],
     "ssas": [
-      "-labelled somatostatin analogues",
       "medical options",
+      "-labelled somatostatin analogues",
       "what is the role of somatostatin analogues"
     ],
     "urinary-free cortisol": [
@@ -935,19 +935,19 @@
       "cht"
     ],
     "cht": [
-      "chemotherapy",
       "the addition of the chemotherapy",
-      "platinum-based chemotherapy",
-      "platinum-based chemo\ntherapy",
       "over platinum-based doublet\nchemotherapy",
-      "over platinum-based doublet chemotherapy",
+      "mainly cytotoxic chemotherapy",
+      "chemotherapy",
+      "platinum-based chemo\ntherapy",
       "with or without prior adjuvant chemotherapy",
-      "the beneficial effects of adjuvant chemotherapy",
-      "mainly cytotoxic chemotherapy"
+      "over platinum-based doublet chemotherapy",
+      "platinum-based chemotherapy",
+      "the beneficial effects of adjuvant chemotherapy"
     ],
     "or systemic therapies": [
-      "with options discussed in these guidelines",
-      "with options\ndiscussed in these guidelines"
+      "with options\ndiscussed in these guidelines",
+      "with options discussed in these guidelines"
     ],
     "with options\ndiscussed in these guidelines": [
       "or systemic therapies"
@@ -956,8 +956,8 @@
       "functioning syndrome"
     ],
     "functioning syndrome": [
-      "in case of\nclinical",
-      "in case of clinical"
+      "in case of clinical",
+      "in case of\nclinical"
     ],
     "and the united states food and drug administration": [
       "fda"
@@ -973,9 +973,9 @@
       "rfa"
     ],
     "rfa": [
+      "for these patients radiofrequency ablation",
       "palliative surgery\nor radiofrequency ablation",
-      "palliative surgery or radiofrequency ablation",
-      "for these patients radiofrequency ablation"
+      "palliative surgery or radiofrequency ablation"
     ],
     "or cryoablation or endobronchial treatment": [
       "ebt"
@@ -987,8 +987,8 @@
       "prrt"
     ],
     "prrt": [
-      "peptide\nreceptor radionuclide therapy",
-      "peptide receptor radionuclide therapy"
+      "peptide receptor radionuclide therapy",
+      "peptide\nreceptor radionuclide therapy"
     ],
     "and interferon- a": [
       "ifna"
@@ -1040,8 +1040,8 @@
       "-fluorouracil"
     ],
     "as alternative second-line": [
-      "in case of\nuncontrolled cs",
-      "in case of uncontrolled cs"
+      "in case of uncontrolled cs",
+      "in case of\nuncontrolled cs"
     ],
     "in case of\nuncontrolled cs": [
       "as alternative second-line"
@@ -1074,8 +1074,8 @@
       "thymic net recurrences may be local"
     ],
     "regional": [
-      "intrathoracic especially\npleural",
-      "intrathoracic especially pleural"
+      "intrathoracic especially pleural",
+      "intrathoracic especially\npleural"
     ],
     "intrathoracic especially\npleural": [
       "regional"
@@ -1085,12 +1085,12 @@
     ],
     "esmo-mcbs": [
       "esmo-magnitude of clinical\nbenefit",
-      "esmo-magnitude of clinical benefit scale",
-      "an esmo magnitude of clinical benefit scale",
-      "esmo-magnitude of\nclinical benefit",
       "an esmo\nmagnitude of clinical benefit scale",
       "esmo-magnitude of clinical benefit",
-      "esmomagnitude of clinical benefit scale"
+      "esmomagnitude of clinical benefit scale",
+      "an esmo magnitude of clinical benefit scale",
+      "esmo-magnitude of clinical benefit scale",
+      "esmo-magnitude of\nclinical benefit"
     ],
     "advanced carcinoids of the lung and thymus": [
       "luna"
@@ -1144,15 +1144,15 @@
       "chuv"
     ],
     "chuv": [
-      "centre hospitalier universitaire vaudois",
-      "centre hospitalier universitaire\nvaudois"
+      "centre hospitalier universitaire\nvaudois",
+      "centre hospitalier universitaire vaudois"
     ],
     "comparing low-dose computed tomography": [
       "ldct"
     ],
     "ldct": [
-      "comparing low-dose computed tomography",
-      "low-dose ct"
+      "low-dose ct",
+      "comparing low-dose computed tomography"
     ],
     "such as lepidic adenocarcinomas": [
       "previously named bronchioloalveolar carcinoma"
@@ -1177,11 +1177,11 @@
       "who"
     ],
     "who": [
+      "the recent world health organization",
       "world health organization",
-      "global statistics",
       "global",
-      "the recent world health organization",
-      "vs universal"
+      "vs universal",
+      "global statistics"
     ],
     "with its further sub-classification of": [
       "surgically resected"
@@ -1196,8 +1196,8 @@
       "ais"
     ],
     "ais": [
-      "the categories adenocarcinoma in situ",
       "proposed that ais be classified as tis",
+      "the categories adenocarcinoma in situ",
       "proposed\nthat ais be classified as tis"
     ],
     "minimally invasive adenocarcinoma": [
@@ -1229,18 +1229,18 @@
       "uicc"
     ],
     "uicc": [
-      "the union for international cancer control",
-      "the union for\ninternational cancer control",
+      "union for international cancer control",
       "union for international\ncancer control",
-      "union for international cancer control"
+      "the union for international cancer control",
+      "the union for\ninternational cancer control"
     ],
     "node and metastasis": [
       "tnm"
     ],
     "tnm": [
-      "tumourenodeemetastasis",
+      "node and metastasis",
       "tumour-node-metastasis",
-      "node and metastasis"
+      "tumourenodeemetastasis"
     ],
     "proposed\nthat ais be classified as tis": [
       "ais"
@@ -1268,9 +1268,9 @@
       "accp"
     ],
     "accp": [
-      "the american college of chest physicians",
+      "the\namerican college of chest physicians",
       "whereas the american college of chest physicians",
-      "the\namerican college of chest physicians"
+      "the american college of chest physicians"
     ],
     "adjuvant chemotherapy": [
       "radiotherapy"
@@ -1282,8 +1282,8 @@
       "vats"
     ],
     "vats": [
-      "or a video-assisted thoracoscopic surgery",
-      "video-assisted thoracic surgery"
+      "video-assisted thoracic surgery",
+      "or a video-assisted thoracoscopic surgery"
     ],
     "based on the lung cancer study group": [
       "lcsg"
@@ -1347,10 +1347,10 @@
       "neo"
     ],
     "neo": [
-      "resection and after",
+      "the\nimmune strategy in the",
       "- immunotherapy is being studied in early nsclc as",
       "immunotherapy is being studied in early nsclc as",
-      "the\nimmune strategy in the",
+      "resection and after",
       "the immune strategy in the"
     ],
     "cl\n\ntreatment of locally advanced stage": [
@@ -1385,8 +1385,8 @@
     ],
     "ests": [
       "and the european\nsociety of thoracic surgeons",
-      "and european society of thoracic surgeons",
-      "and the european society of thoracic surgeons"
+      "and the european society of thoracic surgeons",
+      "and european society of thoracic surgeons"
     ],
     "gv scagliotti": [
       "eds"
@@ -1408,8 +1408,8 @@
       "pulmonology"
     ],
     "pulmonology": [
-      "respiratory oncology unit",
-      "respiratory oncology"
+      "respiratory oncology",
+      "respiratory oncology unit"
     ],
     "edegem": [
       "antwerp"
@@ -1430,11 +1430,11 @@
       "stage iii"
     ],
     "stage iii": [
-      "and unresectable locally advanced",
+      "locally advanced nsclc",
+      "- locally advanced nsclc",
       "unresectable nsclc",
       "treatment of locally advanced stage",
-      "- locally advanced nsclc",
-      "locally advanced nsclc"
+      "and unresectable locally advanced"
     ],
     "in paral\npractice guidelines": [
       "cpgs"
@@ -1446,9 +1446,9 @@
       "see panel members listed in the appendix"
     ],
     "see panel members listed in the appendix": [
-      "experts were involved in this\nconsensus process",
       "experts were involved in this consensus process",
-      "and a general consen\nconsensus process"
+      "and a general consen\nconsensus process",
+      "experts were involved in this\nconsensus process"
     ],
     "experts were involved in this\nconsensus process": [
       "see panel members listed in the appendix"
@@ -1466,8 +1466,8 @@
       "as relative value depends on personal"
     ],
     "respiratory literature": [
-      "especially on exercise\ntesting",
-      "especially on exercise testing"
+      "especially on exercise testing",
+      "especially on exercise\ntesting"
     ],
     "especially on exercise\ntesting": [
       "respiratory literature"
@@ -1581,13 +1581,13 @@
       "pbc"
     ],
     "pbc": [
+      "platinum-based doublet chemotherapy",
       "five cycles of tremelimumab",
-      "five cycles of\n\ntremelimumab",
-      "platinum-based doublet chemotherapy"
+      "five cycles of\n\ntremelimumab"
     ],
     "carboplatin": [
-      "arm b",
-      "arm a"
+      "arm a",
+      "arm b"
     ],
     "arm a": [
       "carboplatin"
@@ -1606,23 +1606,23 @@
       "primary endpoint"
     ],
     "primary endpoint": [
-      "pbc\nsignificantly improved pfs",
-      "significantly improved os",
+      "-year os",
       "pbc significantly improved pfs",
       "level",
-      "-year os"
+      "significantly improved os",
+      "pbc\nsignificantly improved pfs"
     ],
     "besides immune checkpoint\n\ninhibitor": [
       "ici"
     ],
     "ici": [
-      "besides immune checkpoint inhibitor",
       "besides immune checkpoint\n\ninhibitor",
-      "and have no prior immune checkpoint inhibitor"
+      "and have no prior immune checkpoint inhibitor",
+      "besides immune checkpoint inhibitor"
     ],
     "esmo-magnitude of clinical benefit scale": [
-      "mcbs",
-      "esmo-mcbs"
+      "esmo-mcbs",
+      "mcbs"
     ],
     "mcbs": [
       "esmo-magnitude of clinical benefit scale"
@@ -1652,8 +1652,8 @@
       "ttfields"
     ],
     "ttfields": [
-      "tumour treating fields",
-      "tumour treating\nfields"
+      "tumour treating\nfields",
+      "tumour treating fields"
     ],
     "significantly improved os": [
       "primary endpoint"
@@ -1662,14 +1662,14 @@
       "esmo guidelines staff"
     ],
     "esmo guidelines staff": [
+      "jennifer\nlamarre and guy atchison",
       "ioanna ntai and claire bramley",
       "jennifer lamarre and guy atchison",
-      "jennifer\nlamarre and guy atchison",
       "valerie laforest"
     ],
     "valerie laforest": [
-      "esmo guidelines staff",
-      "esmo\nguidelines staff"
+      "esmo\nguidelines staff",
+      "esmo guidelines staff"
     ],
     "esmo\nguidelines staff": [
       "valerie laforest"
@@ -1678,11 +1678,11 @@
       "esmo scientific affairs staff"
     ],
     "esmo scientific affairs staff": [
-      "nicola latino and francesca chiovaro",
-      "nicola latino and\nfrancesca chiovaro",
-      "nicola latino",
+      "nicola\nlatino",
       "nicola\nlatino and francesca chiovaro",
-      "nicola\nlatino"
+      "nicola latino and\nfrancesca chiovaro",
+      "nicola latino and francesca chiovaro",
+      "nicola latino"
     ],
     "bristol\nmyers squibb": [
       "bms"
@@ -1700,8 +1700,8 @@
       "ipsos"
     ],
     "ipsos": [
-      "with a platinum-containing\nregimen",
-      "roche and                                regimen"
+      "roche and                                regimen",
+      "with a platinum-containing\nregimen"
     ],
     "esmo clinical practice guideline": [
       "cpg"
@@ -1719,9 +1719,9 @@
       "ngs"
     ],
     "ngs": [
-      "multiplex platforms",
       "by next-generation sequencing",
-      "such as next-generation sequencing"
+      "such as next-generation sequencing",
+      "multiplex platforms"
     ],
     "egfr fish or immunohistochemistry": [
       "ihc"
@@ -1733,17 +1733,17 @@
       "ntrk"
     ],
     "ntrk": [
-      "- the neurotrophic receptor tyrosine kinase",
-      "or neurotrophic tyrosine receptor kinase",
+      "and the neurotrophic receptor tyrosine\nkinase",
       "or neurotrophic tyrosine\nreceptor kinase",
-      "and the neurotrophic receptor tyrosine\nkinase"
+      "- the neurotrophic receptor tyrosine kinase",
+      "or neurotrophic tyrosine receptor kinase"
     ],
     "detection is reliable by\nin situ hybridisation": [
       "ish"
     ],
     "ish": [
-      "detection is reliable by in situ hybridisation",
-      "detection is reliable by\nin situ hybridisation"
+      "detection is reliable by\nin situ hybridisation",
+      "detection is reliable by in situ hybridisation"
     ],
     "mesenchymal-epithelial transition": [
       "met"
@@ -1781,8 +1781,8 @@
       "fdg"
     ],
     "fdg": [
-      "e\ndeoxy-d-glucose",
-      "-deoxy-d-glucose"
+      "-deoxy-d-glucose",
+      "e\ndeoxy-d-glucose"
     ],
     "union for international\ncancer control": [
       "uicc"
@@ -1811,10 +1811,10 @@
       "mos"
     ],
     "mos": [
-      "and median os",
       "malaysian oncological society",
       "malaysia",
-      "the malaysian oncological society"
+      "the malaysian oncological society",
+      "and median os"
     ],
     "systemic progression\n\nlocal treatment": [
       "surgery or ft"
@@ -1848,15 +1848,15 @@
       "japan"
     ],
     "japan": [
-      "jsmo",
-      "j-alex"
+      "j-alex",
+      "jsmo"
     ],
     "and\nalesia": [
       "asia"
     ],
     "asia": [
-      "and\nalesia",
-      "and alesia"
+      "and alesia",
+      "and\nalesia"
     ],
     "and continue targeted": [
       "not mandatory for decision"
@@ -1889,8 +1889,8 @@
       "mdor"
     ],
     "mdor": [
-      "the\nmedian duration of response",
-      "the median duration of response"
+      "the median duration of response",
+      "the\nmedian duration of response"
     ],
     "tropomyosin receptor tyrosine kinase": [
       "trk"
@@ -1902,9 +1902,9 @@
       "surgery or rt"
     ],
     "surgery or rt": [
+      "- local treatment",
       "oligoprogression\n\nlocal treatment",
       "local treatment",
-      "- local treatment",
       "disease progression\n\nlocal treatment"
     ],
     "or combination therapy with a mek inhibitor": [
@@ -1932,8 +1932,8 @@
       "kras"
     ],
     "kras": [
-      "the kirsten rat sarcoma virus",
-      "the\nkirsten rat sarcoma virus"
+      "the\nkirsten rat sarcoma virus",
+      "the kirsten rat sarcoma virus"
     ],
     "data regarding the role of local ablative therapy": [
       "lat"
@@ -1972,8 +1972,8 @@
       "esmo scientific affairs staff"
     ],
     "and dr svetlana jezdic": [
-      "esmo\nmedical affairs advisor",
       "esmo medical affairs advisor",
+      "esmo\nmedical affairs advisor",
       "esmo medical affairs staff"
     ],
     "esmo\nmedical affairs advisor": [
@@ -1986,8 +1986,8 @@
       "atorg"
     ],
     "atorg": [
-      "asian\nthoracic oncology research group",
-      "asian thoracic oncology research group"
+      "asian thoracic oncology research group",
+      "asian\nthoracic oncology research group"
     ],
     "chinese lung\ncancer research foundation limited": [
       "clcrf"
@@ -2062,8 +2062,8 @@
       "asmac"
     ],
     "asmac": [
-      "s\nde clinique",
-      "s de clinique"
+      "s de clinique",
+      "s\nde clinique"
     ],
     "rzte": [
       "vsao"
@@ -2084,12 +2084,12 @@
       "cancers"
     ],
     "relay": [
-      "advanced non-small-cell lung cancer",
-      "cancer"
+      "cancer",
+      "advanced non-small-cell lung cancer"
     ],
     "non-small-cell lung cancer": [
-      "alesia",
-      "nsclc"
+      "nsclc",
+      "alesia"
     ],
     "alesia": [
       "non-small-cell lung cancer"
@@ -2111,9 +2111,9 @@
       "chmp"
     ],
     "chmp": [
-      "tabrecta - summary of opinion",
       "products for human use",
-      "retsevmo - summary of opinion"
+      "retsevmo - summary of opinion",
+      "tabrecta - summary of opinion"
     ],
     "tabrecta - summary of opinion": [
       "chmp"
@@ -2150,8 +2150,8 @@
     ],
     "jsmo": [
       "the\njapanese society of medical oncology",
-      "the japanese society of medical oncology",
-      "japan"
+      "japan",
+      "the japanese society of medical oncology"
     ],
     "korea": [
       "ksmo"
@@ -2166,10 +2166,10 @@
       "psmo"
     ],
     "psmo": [
-      "the philippine society of medical oncology",
       "and philippine society of medical oncology",
-      "the philippines",
       "and philippine society of medical\noncology",
+      "the philippine society of medical oncology",
+      "the philippines",
       "the philippine society of\nmedical oncology"
     ],
     "singapore": [
@@ -2184,15 +2184,15 @@
       "tos"
     ],
     "tos": [
-      "the taiwan oncology society",
-      "taiwan"
+      "taiwan",
+      "the taiwan oncology society"
     ],
     "and thailand": [
       "tsco"
     ],
     "tsco": [
-      "and thailand",
       "and the\nthai society of clinical oncology",
+      "and thailand",
       "and the thai society of clinical oncology"
     ],
     "and the neurotrophic receptor tyrosine\nkinase": [
@@ -2229,8 +2229,8 @@
       "tmk and hrk"
     ],
     "tmk and hrk": [
-      "only two of the six expert members from the ksmo",
-      "only two of the six\nexpert members from the ksmo"
+      "only two of the six\nexpert members from the ksmo",
+      "only two of the six expert members from the ksmo"
     ],
     "performance status": [
       "ecog ps"
@@ -2266,8 +2266,8 @@
       "such as osimertinib"
     ],
     "such as osimertinib": [
-      "third-generation egfr tkis",
-      "generation tki"
+      "generation tki",
+      "third-generation egfr tkis"
     ],
     "generation tki": [
       "such as osimertinib"
@@ -2306,9 +2306,9 @@
       "traes"
     ],
     "traes": [
-      "treatment-related aes",
+      "treatment-related adverse events",
       "what are the treatment-related adverse events",
-      "treatment-related adverse events"
+      "treatment-related aes"
     ],
     "and have no prior immune checkpoint inhibitor": [
       "ici"
@@ -2326,8 +2326,8 @@
       "jkn"
     ],
     "jkn": [
-      "ishmo\n\nthe jaminan kesehatan nasional",
-      "ishmo\n\n\nthe jaminan kesehatan nasional"
+      "ishmo\n\n\nthe jaminan kesehatan nasional",
+      "ishmo\n\nthe jaminan kesehatan nasional"
     ],
     "there is no regulation of partial coverage": [
       "co-payment"
@@ -2339,8 +2339,8 @@
       "pap"
     ],
     "pap": [
-      "program",
-      "esmo open\n\n\n\nprogram"
+      "esmo open\n\n\n\nprogram",
+      "program"
     ],
     "mandatory national health insurance": [
       "nhi"
@@ -2368,8 +2368,8 @@
       "alk inhibitors"
     ],
     "and atezolizumab": [
-      "in the second-line setting",
-      "in the\nsecond-line setting"
+      "in the\nsecond-line setting",
+      "in the second-line setting"
     ],
     "in the\nsecond-line setting": [
       "and atezolizumab"
@@ -2385,8 +2385,8 @@
       "first-line"
     ],
     "first-line": [
-      "and the alk inhibitors ceritinib and\nbrigatinib",
-      "and the alk inhibitors ceritinib and brigatinib"
+      "and the alk inhibitors ceritinib and brigatinib",
+      "and the alk inhibitors ceritinib and\nbrigatinib"
     ],
     "german": [
       "merck"
@@ -2395,8 +2395,8 @@
       "torg"
     ],
     "torg": [
-      "thoracic oncology research group",
-      "thoracic oncology research\ngroup"
+      "thoracic oncology research\ngroup",
+      "thoracic oncology research group"
     ],
     "and west japan oncology group": [
       "wjog"
@@ -2405,8 +2405,8 @@
       "and west japan oncology group"
     ],
     "product samples": [
-      "non-renumerated",
-      "nonrenumerated"
+      "nonrenumerated",
+      "non-renumerated"
     ],
     "nonrenumerated": [
       "product samples"
@@ -2479,21 +2479,21 @@
       "mnsclc"
     ],
     "mnsclc": [
-      "stage iv metastatic non-small-cell lung cancer",
-      "e-mutant metastatic nsclc"
+      "e-mutant metastatic nsclc",
+      "stage iv metastatic non-small-cell lung cancer"
     ],
     "binimetinib in patients": [
       "pts"
     ],
     "pts": [
-      "versus docetaxel in patients",
       "patients",
-      "therapy in patients",
-      "mo encorafenib plus\n\nbinimetinib in patients",
-      "p repotrectinib in patients",
       "mo encorafenib plus binimetinib in patients",
       "binimetinib in patients",
-      "osimertinib as adjuvant therapy in patients"
+      "therapy in patients",
+      "p repotrectinib in patients",
+      "osimertinib as adjuvant therapy in patients",
+      "versus docetaxel in patients",
+      "mo encorafenib plus\n\nbinimetinib in patients"
     ],
     "mutant advanced non-small cell lung cancer": [
       "nsclc"
@@ -2509,8 +2509,8 @@
     ],
     "treatment of early stages": [
       "stages i-ii",
-      "stages i and ii",
-      "stages i-iiia"
+      "stages i-iiia",
+      "stages i and ii"
     ],
     "stages i-iiia": [
       "treatment of early stages"
@@ -2523,8 +2523,8 @@
     ],
     "chemotherapy": [
       "- everolimus\n   - cht",
-      "adaura",
-      "cht"
+      "cht",
+      "adaura"
     ],
     "the median\nwas not reached": [
       "ne-ne"
@@ -2543,8 +2543,8 @@
       "neo"
     ],
     "or docetaxel or pemetrexed": [
-      "only in\nadenocarcinoma tumours",
-      "only in adenocarcinoma tumours"
+      "only in adenocarcinoma tumours",
+      "only in\nadenocarcinoma tumours"
     ],
     "only in\nadenocarcinoma tumours": [
       "or docetaxel or pemetrexed"
@@ -2553,9 +2553,9 @@
       "port"
     ],
     "port": [
-      "comparing post-operative conformal radiotherapy",
+      "postoperative radiotherapy",
       "post-operative radiotherapy",
-      "postoperative radiotherapy"
+      "comparing post-operative conformal radiotherapy"
     ],
     "treatment of locally advanced stage": [
       "stage iii"
@@ -2594,9 +2594,9 @@
       "pacific"
     ],
     "pacific": [
-      "small-cell lung cancer",
       "concurrent chemoradiation therapy",
-      "unresectable non-small-cell lung cancer"
+      "unresectable non-small-cell lung cancer",
+      "small-cell lung cancer"
     ],
     "adaura": [
       "chemotherapy"
@@ -2605,8 +2605,8 @@
       "including stage ib"
     ],
     "including stage ib": [
-      "approval was based on all patient data",
-      "d approval was based on all patient data"
+      "d approval was based on all patient data",
+      "approval was based on all patient data"
     ],
     "on tumour cells": [
       "as per the\nema-approved indication",
@@ -2649,8 +2649,8 @@
       "egfrm"
     ],
     "nivolumab": [
-      "bristol myers squibb statement on opdivo",
-      "nivo"
+      "nivo",
+      "bristol myers squibb statement on opdivo"
     ],
     "nivo": [
       "nivolumab"
@@ -2659,16 +2659,16 @@
       "chemo"
     ],
     "chemo": [
+      "platinum-based chemotherapy",
       "platinum-doublet chemotherapy",
-      "platinum-doublet\nchemotherapy",
-      "platinum-based chemotherapy"
+      "platinum-doublet\nchemotherapy"
     ],
     "for\nresectable": [
       "ib-iiia"
     ],
     "ib-iiia": [
-      "for\nresectable",
-      "for resectable"
+      "for resectable",
+      "for\nresectable"
     ],
     "lung cancer": [
       "nsclc"
@@ -2692,8 +2692,8 @@
       "diques august pi i sunyer"
     ],
     "department of radiation oncology": [
-      "maastro",
-      "maastro clinic"
+      "maastro clinic",
+      "maastro"
     ],
     "maastro clinic": [
       "department of radiation oncology"
@@ -3215,8 +3215,8 @@
       "rfa"
     ],
     "peptide receptor radionuclide therapy": [
-      "prrt",
-      "- prrt"
+      "- prrt",
+      "prrt"
     ],
     "what is the role of somatostatin analogues": [
       "ssas"
@@ -3423,8 +3423,8 @@
       "fda"
     ],
     "the median duration of response": [
-      "dor",
-      "mdor"
+      "mdor",
+      "dor"
     ],
     "deruxtecan": [
       "fda approved"
@@ -3535,13 +3535,13 @@
       "author"
     ],
     "author": [
+      "hrk",
+      "cew",
       "jchy",
+      "sak",
       "msi",
       "tmk",
-      "ddwl",
-      "cew",
-      "sak",
-      "hrk"
+      "ddwl"
     ],
     "hrk": [
       "author"
@@ -3661,158 +3661,158 @@
   },
   "abbreviations": {
     "esmo": [
+      "european society for medical oncology",
+      "european society for medical\noncology",
+      "the european society for medical oncology",
       "european\nsociety of medical oncology",
       "the following european society for medical oncology",
-      "european society of medical oncology",
-      "european society for medical oncology",
+      "the most recent european society for medical oncology",
       "living guideline\n\nthe following european society for medical oncology",
-      "european society for medical\noncology",
       "european society for\nmedical oncology",
-      "the european society for medical oncology",
-      "the most recent european society for medical oncology"
+      "european society of medical oncology"
     ],
     "asco": [
-      "american society of clinical\noncology",
       "american society of clinical\n\noncology",
-      "american society of clinical oncology",
-      "american\nsociety of clinical oncology",
-      "this american society of clinical oncology",
       "journal of clinical oncology",
-      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc"
+      "american society of clinical\noncology",
+      "american\nsociety of clinical oncology",
+      "the clinical practice guidelines published herein are provided by the american society of clinical oncology inc",
+      "american society of clinical oncology",
+      "this american society of clinical oncology"
     ],
     "aiom": [
-      "italian association\nof medical oncology",
+      "the italian association of medical oncology",
       "italian association of medical oncology",
-      "the italian association of medical oncology"
+      "italian association\nof medical oncology"
     ],
     "nccn": [
-      "american cancer centers",
-      "national comprehensive cancer network"
+      "national comprehensive cancer network",
+      "american cancer centers"
     ],
     "glides": [
+      "ecision support",
       "guidelines into decision\nsupport",
-      "guidelines into decision support",
-      "ecision support"
+      "guidelines into decision support"
     ],
     "glc": [
       "guidelines committee"
     ],
     "mcbs": [
-      "magnitude of clinical benefit score",
+      "magnitude of clinical benefit scale",
       "magnitude\nof clinical benefit score",
-      "magnitude of clinical benefit scale"
+      "magnitude of clinical benefit score"
     ],
     "ema": [
       "european medicines\nagency",
       "european medicines agency"
     ],
     "sclc": [
-      "clinical practice guidelines on small cell lung cancer",
-      "small cell lung cancer",
       "what is the treatment algorithm for patients with small cell lung cancer",
+      "small cell lung cancer",
       "clinical practice guidelines on small cell lung\ncancer",
+      "clinical practice guidelines on small cell lung cancer",
       "what are the recommended treatment options for patients with relapsed small cell lung cancer"
     ],
     "cco": [
       "cancer care ontario"
     ],
     "astro": [
-      "executive summary of an american society for radiation oncology",
-      "executive summary of an american society for\nradiation oncology"
+      "executive summary of an american society for\nradiation oncology",
+      "executive summary of an american society for radiation oncology"
     ],
     "inst": [
-      "merck",
-      "trizell",
-      "regeneron",
-      "lilly",
-      "heart therapeutics",
-      "elevation oncology",
-      "amgen",
-      "janssen oncology",
-      "verastem",
-      "myers squibb",
-      "black diamond therapeutics",
-      "zeneca",
-      "janssen",
-      "guardant health",
-      "palobiofarma",
-      "constellation pharmaceuticals",
-      "immune",
+      "advaxis",
+      "bristol myers squibb",
       "blueprint medicines",
-      "nuvation bio",
-      "pfizer",
-      "therapeutics",
-      "mirati therapeutics",
+      "dizal pharma",
+      "astex pharmaceuticals",
       "revolution medicines",
+      "black diamond therapeutics",
+      "verastem",
+      "heart therapeutics",
+      "sutro biopharma",
+      "novartis",
+      "bristol myers\nsquibb",
+      "merck",
+      "black diamond\ntherapeutics",
+      "therapeutics",
+      "guardant health",
+      "jazz pharmaceuticals",
+      "amgen",
+      "calithera biosciences",
+      "genomics",
       "dohme",
-      "summit therapeutics",
+      "astra zeneca",
       "harpoon therapeutics",
-      "macrogenics",
+      "pfizer",
+      "zeneca canada",
       "kline canada",
-      "jazz pharmaceuticals",
-      "kline",
-      "genentech",
+      "nuvation bio",
+      "turning point therapeutics",
+      "trizell",
+      "immune",
+      "roche",
+      "arcus biosciences",
+      "summit therapeutics",
+      "myers squibb",
+      "lilly",
+      "forward",
+      "regeneron",
       "takeda",
-      "astra zeneca",
-      "genomics",
-      "cullinan oncology",
-      "zeneca canada",
-      "bristol myers\nsquibb",
       "dizal\npharma",
+      "kline",
+      "janssen oncology",
+      "polaris",
+      "mirati therapeutics",
       "puma biotechnology",
-      "advaxis",
-      "novartis",
+      "cullinan oncology",
+      "constellation pharmaceuticals",
       "vivace therapeutics",
-      "turning point therapeutics",
-      "astex pharmaceuticals",
-      "merck serono",
-      "exelixis",
+      "palobiofarma",
+      "bristol myers squibb foundation",
       "bayer",
-      "dizal pharma",
-      "inhibrx",
-      "calithera biosciences",
-      "polaris",
-      "arcus biosciences",
-      "black diamond\ntherapeutics",
-      "boehringer ingelheim",
-      "sutro biopharma",
-      "bristol myers squibb",
-      "forward",
-      "roche",
       "pharmaceuticals",
-      "bristol myers squibb foundation"
+      "boehringer ingelheim",
+      "inhibrx",
+      "exelixis",
+      "merck serono",
+      "janssen",
+      "macrogenics",
+      "zeneca",
+      "elevation oncology",
+      "genentech"
     ],
     "ct": [
-      "the use of computed tomography",
-      "computed tomography",
       "the use of\ncomputed tomography",
-      "clinicians should use a diagnostic chest computed tomography"
+      "clinicians should use a diagnostic chest computed tomography",
+      "the use of computed tomography",
+      "computed tomography"
     ],
     "mri": [
       "what is the role of brain magnetic resonance imaging"
     ],
     "sbrt": [
-      "salvage stereotactic body radiation therapy",
-      "stereotactic body radiotherapy"
+      "stereotactic body radiotherapy",
+      "salvage stereotactic body radiation therapy"
     ],
     "cap": [
       "pathologists",
       "college of american pathologists"
     ],
     "iaslc": [
+      "international association for the\n\nstudy of lung cancer",
+      "international association for\nthe study of lung cancer",
+      "the international association for the study of lung cancer",
+      "the\ninternational association for the study of lung cancer",
       "pathology committee chair for international association for the study of lung cancer",
       "study of lung cancer",
-      "the\ninternational association for the study of lung cancer",
       "pathology committee chair\nfor international association for the study of lung cancer",
-      "international association for the\nstudy of lung cancer",
       "international association for the study of lung cancer",
-      "international association for the\n\nstudy of lung cancer",
-      "the international association for the study of lung cancer",
-      "international association for\nthe study of lung cancer"
+      "international association for the\nstudy of lung cancer"
     ],
     "amp": [
-      "association\nfor molecular pathology",
-      "association for molecular pathology"
+      "association for molecular pathology",
+      "association\nfor molecular pathology"
     ],
     "ihc": [
       "immunohistochemistry"
@@ -3824,11 +3824,11 @@
       "although the results from the mesothelioma and radical surgery"
     ],
     "os": [
-      "the median\noverall survival",
-      "median overall survival",
       "overall survival",
       "the median overall survival",
-      "the only data published thus far pertain to the dual primary end points of overall survival"
+      "the only data published thus far pertain to the dual primary end points of overall survival",
+      "the median\noverall survival",
+      "median overall survival"
     ],
     "elsevier": [
       "clinical lung cancer"
@@ -3837,27 +3837,27 @@
       "one randomized controlled trial"
     ],
     "ps": [
-      "eastern cooperative oncology group performance\nstatus",
-      "eastern cooperative oncology group performance status"
+      "eastern cooperative oncology group performance status",
+      "eastern cooperative oncology group performance\nstatus"
     ],
     "orr": [
       "is result in a lower overall response\nrate",
-      "objective response rate",
       "is result in a lower overall response rate",
+      "objective response rate",
       "reuss et al\n\n\n\nrate"
     ],
     "pci": [
-      "prophylactic cranial irradiation",
-      "what is the role of prophylactic cranial irradiation"
+      "what is the role of prophylactic cranial irradiation",
+      "prophylactic cranial irradiation"
     ],
     "fda": [
-      "entrectinib received food and\ndrug administration",
       "entrectinib received food and drug administration",
-      "osimertinib is approved by both the united states food and drug administration",
-      "food and drug administration",
+      "entrectinib received food and\ndrug administration",
       "osimertinib is approved by both the united states food and\ndrug administration",
-      "united states food and drug administration",
-      "these results led to the food\n\nand drug administration"
+      "these results led to the food\n\nand drug administration",
+      "food and drug administration",
+      "osimertinib is approved by both the united states food and drug administration",
+      "united states food and drug administration"
     ],
     "crs": [
       "cytokine release syndrome"
@@ -3866,44 +3866,44 @@
       "department of surgical sciences"
     ],
     "who": [
-      "the latest world health organization",
+      "the recent world health organization",
       "world health organization",
-      "global statistics",
       "global",
-      "the recent world health organization"
+      "the latest world health organization",
+      "global statistics"
     ],
     "lc": [
-      "these guidelines are restricted to lung carcinoid",
-      "these\nguidelines are restricted to lung carcinoid"
+      "these\nguidelines are restricted to lung carcinoid",
+      "these guidelines are restricted to lung carcinoid"
     ],
     "seer": [
-      "epidemiology and end results",
-      "end results"
+      "end results",
+      "epidemiology and end results"
     ],
     "uicc": [
+      "edition of the union for international cancer control",
       "edition of the union for\ninternational cancer control",
+      "union for\ninternational cancer control",
       "union for international cancer control",
-      "union for international\ncancer control",
-      "edition of the union for international cancer control",
-      "union for\ninternational cancer control"
+      "union for international\ncancer control"
     ],
     "gep": [
-      "based on\napproval and recommendations in gastroenteropancreatic",
-      "based on approval and recommendations in gastroenteropancreatic"
+      "based on approval and recommendations in gastroenteropancreatic",
+      "based on\napproval and recommendations in gastroenteropancreatic"
     ],
     "pth": [
       "annals of oncology\n\n\n\nparathyroid hormone"
     ],
     "rfa": [
+      "for these patients radiofrequency ablation",
       "palliative surgery\nor radiofrequency ablation",
-      "palliative surgery or radiofrequency ablation",
-      "for these patients radiofrequency ablation"
+      "palliative surgery or radiofrequency ablation"
     ],
     "recist": [
       "cs with response evaluation criteria in solid tumours",
-      "measurements and response assessment should follow\nresponse evaluation criteria in solid tumours",
+      "cs with response evaluation criteria\nin solid tumours",
       "measurements and response assessment should follow response evaluation criteria in solid tumours",
-      "cs with response evaluation criteria\nin solid tumours"
+      "measurements and response assessment should follow\nresponse evaluation criteria in solid tumours"
     ],
     "gemox": [
       "oxaliplatin combined with gemcitabine"
@@ -3912,8 +3912,8 @@
       "lanreotide autogel"
     ],
     "chuv": [
-      "centre hospitalier universitaire vaudois",
-      "centre hospitalier universitaire\nvaudois"
+      "centre hospitalier universitaire\nvaudois",
+      "centre hospitalier universitaire vaudois"
     ],
     "nlst": [
       "the much larger national lung cancer screening trial",
@@ -3964,12 +3964,12 @@
       "the thoracic surgery scoring\nsystem"
     ],
     "pulmonology": [
-      "respiratory oncology unit",
-      "respiratory oncology"
+      "respiratory oncology",
+      "respiratory oncology unit"
     ],
     "acs": [
-      "lung cancer screening guidelines published by the american cancer society",
-      "lung cancer screening guidelines published by the\namerican cancer society"
+      "lung cancer screening guidelines published by the\namerican cancer society",
+      "lung cancer screening guidelines published by the american cancer society"
     ],
     "ialt": [
       "some trials"
@@ -3978,11 +3978,11 @@
       "adjuvant navelbine international trialist association"
     ],
     "sabr": [
+      "consolidative stereotactic ablative radiotherapy",
       "what are the indications and recommendations for salvage surgery after stereotactic ablative radiotherapy",
-      "radiographic changes after lung stereotactic ablative radiotherapy",
       "what are the outcomes comparing stereotactic ablative radiotherapy",
-      "radiographic changes after lung stereotactic\nablative radiotherapy",
-      "consolidative stereotactic ablative radiotherapy"
+      "radiographic changes after lung stereotactic ablative radiotherapy",
+      "radiographic changes after lung stereotactic\nablative radiotherapy"
     ],
     "vumc": [
       "vrije\nuniversity medical centre",
@@ -3993,36 +3993,36 @@
       "bemeneed"
     ],
     "bms": [
+      "bristol myers squibb",
       "myers\nsquibb",
+      "myers squibb",
       "bristol myers\nsquibb",
-      "bristol\nmyers squibb",
-      "bristol myers squibb",
-      "myers squibb"
+      "bristol\nmyers squibb"
     ],
     "msd": [
       "dohme"
     ],
     "eortc": [
-      "chair of the european organisation for research and treatment of cancer",
       "chair of the european\norganisation for research and treatment of cancer",
-      "european organisation for research and treatment of cancer",
+      "european\norganisation for research and treatment of cancer",
       "treatment of cancer",
-      "european\norganisation for research and treatment of cancer"
+      "european organisation for research and treatment of cancer",
+      "chair of the european organisation for research and treatment of cancer"
     ],
     "cpg": [
       "clinical practice guideline"
     ],
     "escat": [
       "scale for clinical actionability of\nmolecular targets",
-      "scale for clinical actionability of molecular targets",
-      "targets"
+      "targets",
+      "scale for clinical actionability of molecular targets"
     ],
     "alk": [
       "positive anaplastic lymphoma kinase"
     ],
     "ish": [
-      "detection is reliable by in situ hybridisation",
-      "detection is reliable by\nin situ hybridisation"
+      "detection is reliable by\nin situ hybridisation",
+      "detection is reliable by in situ hybridisation"
     ],
     "cns": [
       "imaging of the central nervous system"
@@ -4041,8 +4041,8 @@
       "interstitial lung disease"
     ],
     "kras": [
-      "the kirsten rat sarcoma virus",
-      "the\nkirsten rat sarcoma virus"
+      "the\nkirsten rat sarcoma virus",
+      "the kirsten rat sarcoma virus"
     ],
     "lat": [
       "data regarding the role of local ablative therapy"
@@ -4058,17 +4058,17 @@
       "lung cancer group and past secretary and current\nchair of the nederlandse vereniging van artsen voor longziekten en tuberculose"
     ],
     "atorg": [
-      "asian\nthoracic oncology research group",
-      "asian thoracic oncology research group"
+      "asian thoracic oncology research group",
+      "asian\nthoracic oncology research group"
     ],
     "clcrf": [
       "chinese lung\ncancer research foundation limited",
       "chinese lung cancer research foundation limited"
     ],
     "csco": [
-      "chinese\nsociety of clinical oncology",
       "chinese society of clinical oncology",
-      "china"
+      "china",
+      "chinese\nsociety of clinical oncology"
     ],
     "hkcf": [
       "hong kong cancer fund"
@@ -4087,13 +4087,13 @@
       "research to practice"
     ],
     "samo": [
-      "president of swiss\nacademy of multidisciplinary oncology",
-      "president of swiss academy of multidisciplinary oncology"
+      "president of swiss academy of multidisciplinary oncology",
+      "president of swiss\nacademy of multidisciplinary oncology"
     ],
     "sakk": [
       "research",
-      "president of lung group for swiss group for clinical cancer\nresearch",
-      "president of lung group for swiss group for clinical cancer research"
+      "president of lung group for swiss group for clinical cancer research",
+      "president of lung group for swiss group for clinical cancer\nresearch"
     ],
     "etop": [
       "european thoracic oncology platform"
@@ -4102,8 +4102,8 @@
       "international breast cancer study group"
     ],
     "aacr": [
-      "partners member of american association of cancer research",
-      "partners member\nof american association of cancer research"
+      "partners member\nof american association of cancer research",
+      "partners member of american association of cancer research"
     ],
     "asmac": [
       "clinique"
@@ -4113,20 +4113,20 @@
     ],
     "chmp": [
       "summary of opinion",
-      "committee for medicinal products for human use",
-      "products for human use"
+      "products for human use",
+      "committee for medicinal products for human use"
     ],
     "paga": [
       "asian adapted"
     ],
     "ishmo": [
-      "indonesia",
       "indonesian society\nof hematology and medical oncology",
-      "indonesian society of hematology and medical oncology"
+      "indonesian society of hematology and medical oncology",
+      "indonesia"
     ],
     "jsmo": [
-      "japanese society of medical oncology",
-      "japan"
+      "japan",
+      "japanese society of medical oncology"
     ],
     "ksmo": [
       "korea",
@@ -4137,9 +4137,9 @@
       "malaysia"
     ],
     "psmo": [
-      "philippine society of\nmedical oncology",
-      "philippine society of medical\noncology",
       "philippines",
+      "philippine society of medical\noncology",
+      "philippine society of\nmedical oncology",
       "philippine society of medical oncology"
     ],
     "sso": [
@@ -4148,8 +4148,8 @@
       "singapore"
     ],
     "tos": [
-      "taiwan oncology society",
-      "taiwan"
+      "taiwan",
+      "taiwan oncology society"
     ],
     "tsco": [
       "thai society of clinical oncology",
@@ -4163,31 +4163,31 @@
       "national medical products\nadministration"
     ],
     "nmpa": [
-      "chinese national medical products administration",
-      "chinese national\nmedical products administration"
+      "chinese national\nmedical products administration",
+      "chinese national medical products administration"
     ],
     "jkn": [
       "the jaminan kesehatan nasional"
     ],
     "fornas": [
-      "na\ntional drug formulary",
       "national standard of medication list",
       "national standard of\nmedication list",
-      "national drug formulary"
+      "national drug formulary",
+      "na\ntional drug formulary"
     ],
     "pap": [
       "open\n\n\n\nprogram"
     ],
     "pdma": [
-      "it may take\nfrom several months to years for the pharmaceuticals and\nmedical devices agency",
-      "it may take from several months to years for the pharmaceuticals and medical devices agency"
+      "it may take from several months to years for the pharmaceuticals and medical devices agency",
+      "it may take\nfrom several months to years for the pharmaceuticals and\nmedical devices agency"
     ],
     "nhi": [
       "national health insurance"
     ],
     "torg": [
-      "thoracic oncology research group",
-      "thoracic oncology research\ngroup"
+      "thoracic oncology research\ngroup",
+      "thoracic oncology research group"
     ],
     "wjog": [
       "west japan oncology group"
@@ -4196,8 +4196,8 @@
       "trial steering committee"
     ],
     "idmc": [
-      "committee",
-      "independent data monitoring committee"
+      "independent data monitoring committee",
+      "committee"
     ],
     "ukiog": [
       "ireland oesophagogastric group"
@@ -4295,10 +4295,10 @@
       "diffuse idiopathic pulmonary neuroendocrine cell hyperplasia"
     ],
     "port": [
-      "postoperative radiotherapy",
-      "radiotherapy",
       "what is the current evidence and recommendation for postoperative radiotherapy",
-      "what are the outcomes and recommendations for postoperative radiotherapy"
+      "postoperative radiotherapy",
+      "what are the outcomes and recommendations for postoperative radiotherapy",
+      "radiotherapy"
     ],
     "i-v": [
       "classification system showing five levels of evidence"

logs/app.log

@@ -9262,3 +9262,66 @@ ImportError: cannot import name 'store_user_question' from 'core.tools' (d:\Work
 2025-11-16 14:31:54,318 - AgenticMedicalRAG - INFO - LLM initialized successfully
 2025-11-16 14:31:54,319 - AgenticMedicalRAG - INFO - 🔄 Background Init: All components initialized successfully (100%)
 2025-11-16 14:31:54,319 - AgenticMedicalRAG - INFO - ✅ Background initialization completed successfully
+2025-11-17 18:58:17,162 - AgenticMedicalRAG - INFO - Configuration validation completed
+2025-11-17 18:58:18,680 - AgenticMedicalRAG - INFO - Loaded 1085 learned synonyms from cache
+2025-11-17 18:58:19,132 - AgenticMedicalRAG - INFO - 🚀 Starting background initialization...
+2025-11-17 18:58:19,133 - AgenticMedicalRAG - INFO - 🔄 Background Init: Starting background initialization... (0%)
+2025-11-17 18:58:19,134 - AgenticMedicalRAG - INFO - 🔄 Background Init: Loading embedding model... (10%)
+2025-11-17 18:58:19,134 - AgenticMedicalRAG - INFO - Loading embedding model (first time)...
+2025-11-17 18:58:26,904 - AgenticMedicalRAG - INFO - Embedding model loaded successfully
+2025-11-17 18:58:26,905 - AgenticMedicalRAG - INFO - 🔄 Background Init: Embedding model loaded successfully (40%)
+2025-11-17 18:58:26,905 - AgenticMedicalRAG - INFO - 🔄 Background Init: Initializing retrievers and loading chunks... (50%)
+2025-11-17 18:58:26,905 - AgenticMedicalRAG - INFO - 🔄 Initializing retrievers (first time use)...
+2025-11-17 18:58:26,905 - AgenticMedicalRAG - INFO - 🔄 Processing new data and updating vector store if needed...
+2025-11-17 18:58:27,057 - AgenticMedicalRAG - INFO - 📦 Loading chunks cache for BM25 retriever...
+2025-11-17 18:58:27,094 - AgenticMedicalRAG - INFO - 🔍 Creating vector retriever...
+2025-11-17 18:58:27,095 - AgenticMedicalRAG - INFO - 📝 Creating BM25 retriever...
+2025-11-17 18:58:27,964 - AgenticMedicalRAG - INFO - 🔄 Creating hybrid retriever...
+2025-11-17 18:58:27,964 - AgenticMedicalRAG - INFO - ✅ Retrievers initialized successfully.
+2025-11-17 18:58:27,964 - AgenticMedicalRAG - INFO - 🔄 Background Init: Retrievers initialized successfully (90%)
+2025-11-17 18:58:27,965 - AgenticMedicalRAG - INFO - 🔄 Background Init: Learning medical terminology from corpus... (92%)
+2025-11-17 18:58:31,275 - AgenticMedicalRAG - INFO - Saved learned terms to cache
+2025-11-17 18:58:31,276 - AgenticMedicalRAG - INFO - Learned medical terminology from 1000 documents
+2025-11-17 18:58:31,276 - AgenticMedicalRAG - INFO - 🔄 Background Init: Warming up LLM... (97%)
+2025-11-17 18:58:31,276 - AgenticMedicalRAG - INFO - Initializing LLM (first time)...
+2025-11-17 18:58:32,024 - AgenticMedicalRAG - INFO - LLM initialized successfully
+2025-11-17 18:58:32,025 - AgenticMedicalRAG - INFO - 🔄 Background Init: All components initialized successfully (100%)
+2025-11-17 18:58:32,025 - AgenticMedicalRAG - INFO - ✅ Background initialization completed successfully
+2025-11-17 18:59:13,558 - AgenticMedicalRAG - INFO - Processing user input (attempt 1): Give me the options for first line treatment for N...
+2025-11-17 18:59:15,953 - AgenticMedicalRAG - INFO - No specific provider - querying each provider separately for balanced results
+2025-11-17 18:59:15,953 - AgenticMedicalRAG - INFO - Querying provider: ASCO
+2025-11-17 18:59:16,579 - AgenticMedicalRAG - INFO - Hybrid search returned 1 unique documents (query expansion: False)
+2025-11-17 18:59:16,618 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-17 18:59:16,619 - AgenticMedicalRAG - INFO - Retrieved 1 documents from ASCO
+2025-11-17 18:59:16,619 - AgenticMedicalRAG - INFO - Querying provider: ESMO
+2025-11-17 18:59:16,693 - AgenticMedicalRAG - INFO - Hybrid search returned 6 unique documents (query expansion: False)
+2025-11-17 18:59:16,696 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-17 18:59:16,697 - AgenticMedicalRAG - INFO - Retrieved 6 documents from ESMO
+2025-11-17 18:59:16,697 - AgenticMedicalRAG - INFO - Querying provider: IASLC
+2025-11-17 18:59:16,769 - AgenticMedicalRAG - INFO - Hybrid search returned 0 unique documents (query expansion: False)
+2025-11-17 18:59:16,769 - AgenticMedicalRAG - INFO - Querying provider: NCCN
+2025-11-17 18:59:16,842 - AgenticMedicalRAG - INFO - Hybrid search returned 0 unique documents (query expansion: False)
+2025-11-17 18:59:16,842 - AgenticMedicalRAG - INFO - Querying provider: NICE
+2025-11-17 18:59:16,912 - AgenticMedicalRAG - INFO - Hybrid search returned 5 unique documents (query expansion: False)
+2025-11-17 18:59:16,915 - AgenticMedicalRAG - INFO - Enriched 1 documents with surrounding context pages
+2025-11-17 18:59:16,916 - AgenticMedicalRAG - INFO - Retrieved 5 documents from NICE
+2025-11-17 18:59:38,154 - AgenticMedicalRAG - INFO - Successfully processed user input: Give me the options for first line treatment for N...
+2025-11-17 18:59:38,154 - AgenticMedicalRAG - INFO - Performing background validation...
+2025-11-17 18:59:39,069 - AgenticMedicalRAG - INFO - Medical answer validator initialized successfully
+2025-11-17 18:59:39,069 - AgenticMedicalRAG - INFO - GitHub token configured: ghp_KWH...dnCc
+2025-11-17 18:59:39,069 - AgenticMedicalRAG - INFO - GitHub storage initialized for MoazEldsouky/cloud-data-store
+2025-11-17 18:59:40,033 - AgenticMedicalRAG - INFO - Found 23 existing evaluations in GitHub
+2025-11-17 18:59:40,033 - AgenticMedicalRAG - INFO - Next interaction ID will be: 24
+2025-11-17 18:59:40,034 - AgenticMedicalRAG - INFO - Starting validation for interaction 24
+2025-11-17 19:00:00,170 - AgenticMedicalRAG - INFO - Attempting to save evaluation with ID: 24
+2025-11-17 19:00:00,170 - AgenticMedicalRAG - INFO - GitHub storage instance obtained, calling save_validation_results...
+2025-11-17 19:00:00,171 - AgenticMedicalRAG - INFO - Attempt 1/3: Loading existing evaluations from GitHub...
+2025-11-17 19:00:02,914 - AgenticMedicalRAG - INFO - Successfully loaded 23 existing evaluations
+2025-11-17 19:00:02,915 - AgenticMedicalRAG - INFO - Adding new evaluation with ID: 24
+2025-11-17 19:00:02,915 - AgenticMedicalRAG - INFO - Appended new evaluation. Total count: 24
+2025-11-17 19:00:03,938 - AgenticMedicalRAG - INFO - Uploading to GitHub: medical_data/evaluation_results.json (size: 879332 bytes)
+2025-11-17 19:00:08,498 - AgenticMedicalRAG - INFO - ✓ Successfully uploaded medical_data/evaluation_results.json to GitHub
+2025-11-17 19:00:08,500 - AgenticMedicalRAG - INFO - ✓ Successfully saved evaluation 24. Total evaluations now: 24
+2025-11-17 19:00:08,501 - AgenticMedicalRAG - INFO - ✓ Evaluation saved to GitHub successfully with ID: 24
+2025-11-17 19:00:08,502 - AgenticMedicalRAG - INFO - Background validation completed - Interaction ID: 24
+2025-11-17 19:00:08,502 - AgenticMedicalRAG - INFO - Validation scores - Overall: 90/100, Accuracy: 95/100, Coherence: 90/100, Relevance: 88/100